Search bioRxiv⌕ Search

Biology subjects

Wallace, C.

Publications and source records attributed to Wallace, C..

At least 19 recordsLinked to original sources

Genomic foundation models do not yet boost common variant discovery beyond standard functional annotations

Genomic foundation models (GFMs) use large-scale AI to model genetic sequences and their influence on molecular phenotypes. While GFMs have shown promise in rare variant analysis, their utility for common variant discovery remains untested. Using the surrogate functional false discovery rate framework for functionally informed GWAS discovery, we compared standard functional annotations (baselineLD) with annotations derived from three leading GFMs: the sequence-to-function models AlphaGenome and Borzoi, and the genomic language model GPN-Star. Across 27 UK Biobank traits, GPN-Star decreased locus discovery relative to a standard GWAS, whereas AlphaGenome and Borzoi increased discovery but by less than baselineLD (medians 1.8%, 3.8%, and 5.1%). When we combined the GFM and baselineLD annotations, there was no increase over baselineLD alone (median changes -0.1% to 0.2%), suggesting that AlphaGenome and Borzoi mostly capture information already in baselineLD. Thus, GFMs may require larger corpora or trait-specific feature engineering to improve discovery beyond standard functional annotations.

genomics↗

Thymidine Phosphorylase Drives SARS-CoV-2 Spike Protein-Induced Lung Tumorigenesis

Rationale and ObjectivesCOVID-19 survivors exhibit increased interstitial lung fibrosis, a known risk factor for lung cancer. We investigated whether SARS-CoV-2 Spike protein (SP)-induced lung injury and elevated thymidine phosphorylase (TYMP) promote lung tumorigenesis. MethodsA TriNetX retrospective cohort analysis was combined with mechanistic studies in K18-hACE2TG and K18-hACE2TG/Tymp-/- mice. Mice received intratracheal SP or control lysate followed by a urethane-induced lung cancer protocol. Lung injury, inflammation, thrombosis, fibrosis, STAT3 activation, cytokine profiles, and tumor burden were assessed. In vitro assays evaluated SP- and RBD-induced ACE2 processing. ResultsPropensity score-matched TriNetX cohorts demonstrated an increased lung cancer risk after COVID-19, particularly among current smokers (n = 166,807; RR 1.22; HR 1.50; P < .001). In mice, SP induced acute lung injury, neutrophil infiltration, and microthrombi, which were reduced in TYMP-deficient mice. SP markedly increased lung tumor incidence and aggressiveness, whereas TYMP deficiency reduced tumor formation from 50% to 18% of lung lobes. SP-induced STAT3 upregulation and collagen deposition were significantly attenuated in K18-hACE2TG/Tymp-/- mice. Cytokine profiling revealed a tumor-promoting, myeloid-dominant inflammatory milieu in K18-hACE2TG mice, in contrast to a T cell-inflamed, anti-tumor profile in K18-hACE2TG/Tymp-/- mice. SP and RBD altered ACE2 processing, generating lower-molecular-weight fragments consistent with enhanced turnover. ConclusionsSARS-CoV-2 SP drives lung injury, fibrosis, and tumorigenesis through a TYMP-dependent mechanism involving STAT3 signaling and inflammatory microenvironment remodeling. COVID-19 significantly increases lung cancer risk, especially in current smokers. TYMP represents a potential therapeutic target to mitigate long-term pulmonary consequences of COVID-19.

cell biology↗

Differential Tissue Coupled Powering for Battery-Free Injectable Electroceuticals

Electroceutical implants that deliver targeted neural stimulation have shown therapeutic potential for a wide range of neurological and peripheral disorders, yet wirelessly powering ultra-miniaturized, fully injectable systems remains a critical challenge. Here we report a Thread-like Injectable Neural TechnologY (TINY), powered via a differential tissue-coupled powering (DTCP) scheme. DTCP employs mid-frequency differential potentials applied across external electrodes on a compact, wearable transmitter to deliver energy through tissue to an ultra-miniaturized, thread-like implant that integrates a custom ASIC and PEDOT-coated receiver and stimulation electrodes. Benchtop experiments in agar phantoms characterize the power-transfer efficiency (PTE) and reveal that PTE increases with implant length while maintaining strong tolerance to angular misalignment. In vivo tests in rat hindlimbs further demonstrate wireless activation of the sciatic nerve through tissue at centimeter-scale depths, confirming effective transcutaneous energy delivery for neurostimulation. A 20-day implantation study shows stable positioning of the device with minimal tissue response, indicating excellent chronic compatibility. These findings address long-standing challenges in wirelessly powering injectable electroceuticals and establish DTCP as a scalable and alignment-robust powering strategy for future minimally invasive neuromodulation therapies.

bioengineering↗

Systematic comparison of colocalization methods using protein quantitative trait loci

Colocalization is frequently performed as a step to triage findings from genetic investigations linking molecular and disease data. However, the reliability and consistency of the various colocalization methods is not well understood. In particular, it is unclear whether a non-colocalization result should be taken as a definitive sign that two traits do not share a genetic cause in the region of interest, or merely as suggestive evidence. We use protein QTL data to benchmark four colocalization methods (coloc, coloc-SuSiE, prop-coloc, and colocPropTest), considering whether the methods conclude there is colocalization between datasets representing associations with the same protein. We consider a baseline scenario in which the associations come from the same dataset split in half at random, and scenarios in which the associations are with the same protein, but measured on different platforms or in different populations. In the baseline scenario, all methods report colocalization for the majority of proteins. In other scenarios, methods do not consistently report colocalization, they often report non-colocalization, and they often disagree. In the worst-case scenario, colocalization was only agreed by all four methods for 20% of proteins, despite our experiment being constructed to select for cases where colocalization is expected. This suggests caution in performing and interpreting colocalization analyses is warranted.

genetics↗

Variable information across SNPs in GWAS data can cause false rejections of colocalisation which can be resolved by proportional colocalisation tests

Fine-mapping is now a standard post-GWAS analysis, but it has been shown to be potentially inaccurate for large meta-analysis GWAS. We show how this can be caused by variable amounts of statistical information between variants, e.g. due to variable sample sizes, which arise widely in meta-analyses, or due to variable imputation accuracy or call rate. This effect becomes more pronounced as sample sizes become larger, such that small differences in information available at different variants can lead to large errors in credible set predictions. Here, we show this inaccuracy propagates to the colocalisation method coloc, yielding confident but incorrect inference. We propose an adaptation of the proportional colocalisation test, which avoids any fine-mapping inference as an alternative to fine-mapping based colocalisation. This method was originally superseded by coloc because the null hypothesis is colocalization, and because it can have low power in genetic regions with many variants. Our adaptation resolves this second issue, and simulations demonstrate that our approach accurately resolves false coloc inferences. However, the first issue remains, such that we suggest proportional colocalisation is used as an accompaniment to fine-mapping-based coloc. Our findings also emphasize the need for new methodologies in fine-mapping, particularly as GWAS sample sizes grow, to ensure accurate fine-mapping inference.

bioinformatics↗

Polymorphic tandem repeats shape single-cell gene expression across the immune landscape

Tandem repeats (TRs) - highly polymorphic, repetitive sequences across the human genome - are important regulators of gene expression but remain underexplored due to challenges in accurate genotyping and analysis1. Here, we generate new whole genome and single-cell RNA sequencing from >5.4 million blood-derived cells across 1,925 individuals in two cohorts [Cuomo et al., accompanying manuscript], and perform meta-analysis to characterize the impact of variation in >1.7 million TR loci on immune cell type-specific gene expression. We identify >69,000 single-cell expression TR loci (sc-eTRs), 30.7% of which are specific to one of 28 immune cell types, and reveal dynamic regulatory effects using cell-state inference. Matched single-cell ATAC sequencing profiles from >3.4 million nuclei in 922 individuals [Xue et al., accompanying manuscript]. uncover chromatin accessibility QTLs for nearly one-third of expression-associated TRs, supporting coordinated effects on cis-regulatory architecture. Fine-mapping implicates 1,490 TRs as candidate causal drivers of gene expression in 6.1% of tested genes, and colocalization analyses highlight >200 genes in which TRs likely mediate genetic associations with immune and hematological traits. Together, these results provide a genome-wide, multiomic view of TR-mediated regulation in the human immune system, establishing TRs as key contributors to cell type-specific regulatory variation and complex trait architecture.

genomics↗

Variant-specific priors in colocalisation analysis

Linking GWAS variants to their causal gene remains an ongoing challenge. A widely used method for performing this analysis is the coloc package for statistical colocalisation analysis, which can be used to link GWAS and eQTL associations. Currently, coloc assumes that all variants in a region are equally likely to be causal, despite the success of fine-mapping methods that use additional information to adjust their prior probabilities. In this paper we propose and implement an approach for specifying variant-specific prior probabilities in the coloc method. We describe and compare six source of information for specifying prior probabilities: non-coding constraint, enhancer-gene link scores, the output of the PolyFun method and three estimates of eQTL-TSS distance densities. Using simulations and analysis of ground-truth pQTL-eQTL colocalisations we show that variant-specific priors, particularly the eQTL-TSS distance density priors, can improve colocalisation performance. Furthermore, across GWAS- eQTL colocalisations variant-specific priors changed colocalisation significance in up to 13.5% of colocalisations, at some loci revealing the likely causal gene.

genetics↗

Semi-supervised Bayesian integration of multiple spatial proteomics datasets

The subcellular localisation of proteins is a key determinant of their function. High-throughput analyses of these localisations can be performed using mass spectrometry-based spatial proteomics, which enables us to examine the localisation and relocalisation of proteins. Furthermore, complementary data sources can provide additional sources of functional or localisation information. Examples include protein annotations and other high-throughput omic assays. Integrating these modalities can provide new insights as well as additional confidence in results, but existing approaches for integrative analyses of spatial proteomics datasets are limited in the types of data they can integrate and do not quantify uncertainty. Here we propose a semi-supervised Bayesian approach to integrate spatial proteomics datasets with other data sources, to improve the inference of protein sub-cellular localisation. We demonstrate our approach outperforms other transfer-learning methods and has greater flexibility in the data it can model. To demonstrate the flexibility of our approach, we apply our method to integrate spatial proteomics data generated for the parasite Toxoplasma gondii with time-course gene expression data generated over its cell cycle. Our findings suggest that proteins linked to invasion organelles are associated with expression programs that peak at the end of the first cell-cycle. Furthermore, this integrative analysis divides the dense granule proteins into heterogeneous populations suggestive of potentially different functions. Our method is disseminated via the mdir R package available on the lead authors Github. Author summaryProteins are located in subcellular environments to ensure that they are near their interaction partners and occur in the correct biochemical environment to function. Where a protein is located can be determined from a number of data sources. To integrate diverse datasets together we develop an integrative Bayesian model to combine the information from several datasets in a principled manner. We learn how similar the dataset are as part of the modelling process and demonstrate the benefits of integrating mass-spectrometry based spatial proteomics data with timecourse gene-expression datasets.

systems biology↗

Imputation of cell-type specific expression using RNA-seq data from mixed cell populations

Gene expression studies often use bulk RNA sequencing of mixed cell populations because single cell or sorted cell sequencing may be prohibitively expensive. However, mixed cell studies may miss expression patterns that are restricted to specific cell populations. Computational deconvolution can be used to estimate cell fractions from bulk expression data and infer average cell-type expression in a set of samples (eg cases or controls), but imputing sample-level cell-type expression is required for more detailed analyses, such as relating expression to quantitative traits, and is less commonly addressed. Here, we assessed the accuracy of imputing sample-level cell-type expression using a real dataset where mixed peripheral blood mononuclear cells (PBMC) and sorted (CD4, CD8, CD14, CD19) RNA sequencing data were generated from the same subjects (N=158), and pseudobulk datasets synthesised from eQTLgen single cell RNA-seq data. We compared three domain-specific methods, CIBERSORTx, bMIND and debCAM/swCAM, and two cross-domain machine learning methods, multiple response LASSO and ridge, that had not been used for this task before. We also assessed the methods according to their ability to recover differential gene expression (DGE) results. LASSO/ridge showed higher sensitivity but lower specificity for recovering DGE signals seen in observed data compared to deconvolution methods, although LASSO/ridge had higher area under curves than deconvolution methods. Machine learning methods have the potential to outperform domain-specific methods when suitable training data are available. Author SummaryNumerous studies have demonstrated that gene expression in particular subsets of immune cells plays a critical role in the development of diseases and response to treatment. By profiling gene expression from these cells, we can identify disease-relevant genes, comprehend their functions in the disease or response to treatment, and potentially pave the way for screening and patient stratification for prevention and treatment. However, the current cost of single-cell RNA sequencing is too high for large-scale expression profiling analysis. Therefore, an alternative approach is to computationally estimate cell-type specific expression from mixed cell populations, which has been less explored in the field. With this in mind, we proposed using machine learning approaches, multiple response LASSO and ridge, and applied them to synthesised datasets and real-world data where gene expression was measured in mixed and pure cell populations of the same subjects. We compared them to standard methods in the field, and evaluated the accuracy of predicted expression as well as the ability to reconstruct differentially expressed gene signals. Our results revealed that the LASSO/ridge algorithms performed better than existing methods in recovering differentially expressed gene signals, highlighting their potential applications to impute the cell-type expression.

bioinformatics↗

Diazoxide/dibenozylmethane treatment mitigates spatial memory deficits and pathology and up regulates protective genes in an Alzheimer's transgenic rat model

INTRODUCTIONAlzheimers disease (AD) is a multifactorial disease for which therapeutic efficacy should benefit from a multi-target approach. Thus, we evaluated a combined chronic treatment with diazoxide (DZ) and dibenzoylmethane (DIB). DZ is a potassium channel activator. DIB counteract eIF2-P-driven stress responses. The individual therapeutic benefits of each drug on attenuating neurodegeneration and apoptosis were previously examined, but not as a combined treatment. METHODSWe evaluated the efficacy of chronic DZ/DIB treatment on TgF344-AD rats (Tg-AD) at 4- and 11-months of age and wild-type littermates. Spatial working memory was assessed with the radial 8-arm maze, and AD pathology by immunohistochemistry. We used RNA sequencing for transcriptome analysis. RESULTSDZ/DIB-treatment mitigated the spatial memory deficits as well as the buildup of hippocampal A{beta} plaques and tau PHF exhibited by 11-month Tg-AD rats. The DZ/DIB-treatment had no effect on wild-type littermates. We did not detect AD-related deficits in untreated 4-month Tg-AD rats, but DZ/DIB-treatment altered their transcriptome. DZ/DIB-treatment of 4-month Tg-AD rats upregulated several genes normally downregulated in AD and/or aging. Expression of two potential early biomarkers for AD, EGR2 (early growth response 2) and HISIT1H2AA (histone H2AA), were also altered by the DZ/DIB treatment in 4-month Tg-AD rats. The treatment reduced levels of eIF2, a protein involved in abnormal translational repression and a contributing factor to neuronal loss. DISCUSSIONThis preclinical study represents the first report on the combined DZ/DIB-treatment. Besides the benefits of this treatment on spatial memory and AD pathology, we identified two potential early AD biomarkers. Furthermore, the DZ/DIB-treatment prevented downregulation of genes associated with AD and/or aging. Overall, our results strongly support that the combination DZ/DIB-treatment mitigates AD pathology. Evaluations across multiple AD-related models are warranted to further corroborate that the DZ/DIB combination is a candidate treatment for AD. HighlightsO_LIDZ/DIB treatment improves cognitive deficits and AD pathology in TgF344-AD rats C_LIO_LIEGR2 and HISIT1H2AA genes are potential early AD biomarkers in TgF344-AD rats C_LIO_LIDZ/DIB treatment of 4-month TgF344-AD rats blocks downregulation of AD/aging genes C_LI RESEARCH IN CONTEXT1. Systematic Review: We reviewed the literature using traditional sources (e.g., PubMed) to assess the status of DZ and DIB treatment individually in preclinical studies in animal models. To our knowledge there is no data with this chronic combined treatment. 2. Interpretation: Treatment takes advantage of a polypharmacological approach to AD therapeutics, considering the multifactorial nature of AD. DZ and DIB individually have been successful in mitigating hippocampal AD pathology but their combined effects were unknown, particularly in a rodent model that shows a more complete disease progression that incorporates aging as a risk factor. The effects of the treatment go beyond previous data in individual DZ and DIB treatment, supporting the need for combination drug treatments to treat a multifactorial disorder. 3. Future Directions: Investigate the potential of DZ/DIB treatment to stop the progression or ameliorate AD pathology when administered at a later age, when pathology is first detected. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=138 HEIGHT=200 SRC="FIGDIR/small/555966v1_ufig1.gif" ALT="Figure 1"> View larger version (23K): org.highwire.dtl.DTLVardef@7cc6a0org.highwire.dtl.DTLVardef@1d468feorg.highwire.dtl.DTLVardef@390f19org.highwire.dtl.DTLVardef@e40c8_HPS_FORMAT_FIGEXP M_FIG C_FIG

neuroscience↗

Shared and distinct molecular effects of regulatory genomic variants provide insight into mechanisms of distal enhancer-promoter communication

Gene enhancers often form long-range contacts with promoters, but it remains unclear if enhancer activity and their chromosomal contacts are mediated by the same DNA sequences and recruited factors. We studied the effects of expression quantitative trait loci (eQTLs) on enhancer activity and promoter contacts in primary monocytes isolated from 34 individuals. Using eQTL-Capture Hi-C and a Bayesian approach considering both intra- and inter-individual variation, we initially detected 19 eQTLs associated with enhancer-eGene promoter contacts, most of which also associated with enhancer accessibility and activity. Capitalising on these shared effects, we devised a multi-modality Bayesian strategy, which identified 629 "trimodal QTLs" jointly associated with enhancer accessibility, eGene promoter contact, and gene expression. Causal mediation analysis and CRISPR interference revealed causal relationships between these three modalities. Many detected QTLs overlapped disease susceptibility loci and influenced the predicted binding of myeloid transcription factors, including SPI1, GABPB and STAT3. Additionally, a variant associated with PCK2 promoter contact directly disrupted a CTCF binding motif and impacted promoter insulation from downstream enhancers. Jointly, our findings suggest an inherent genetic link between the activity and connectivity of enhancers with relevance for human disease, and highlight the role of genetically-determined chromatin boundaries in gene control.

genetics↗

CoPheScan: phenome-wide association studies accounting for linkage disequilibrium

Phenome-wide association studies (PheWAS) facilitate the discovery of associations between a single genetic variant with multiple phenotypes. For variants which impact a specific protein, this can help identify additional therapeutic indications or on-target side effects of intervening on that protein. However, PheWAS is restricted by an inability to distinguish confounding due to linkage disequilibrium (LD) from true pleiotropy. Here we describe CoPheScan (Coloc adapted Phenome-wide Scan), a Bayesian approach that enables an intuitive and systematic exploration of causal associations while simultaneously addressing LD confounding. We demonstrate its performance through simulation, showing considerably better control of false positive rates than a conventional approach not accounting for LD. We used CoPheScan to perform PheWAS of protein-truncating variants and fine-mapped variants from disease and pQTL studies, in 2275 disease phenotypes from the UK Biobank. Our results identify the complexity of known pleiotropic genes such as APOE, and suggest a new causal role for TGM3 in skin cancer.

genetics↗

A disease-associated gene desert orchestrates macrophage inflammatory responses via ETS2

Increasing global rates of autoimmune and inflammatory disease present a burgeoning threat to human health1. This is compounded by the limited efficacy of available treatments1 and high failure rates during drug development2 - underscoring an urgent need to better understand disease mechanisms. Here we show how genetics could address this challenge. By investigating an intergenic haplotype on chr21q22, independently linked to inflammatory bowel disease (IBD), ankylosing spondylitis, primary sclerosing cholangitis and Takayasus arteritis3-6, we discover that the causal gene, ETS2, is a master regulator of inflammatory responses in human macrophages and delineate how the risk haplotype increases ETS2 expression. Genes regulated by ETS2 were prominently expressed in affected tissues from chr21q22-associated diseases and more enriched for IBD GWAS hits than almost all previously described pathways. Overexpressing ETS2 in resting macrophages produced an activated effector state that phenocopied intestinal macrophages from IBD7, with upregulation of multiple drug targets including TNF and IL-23. Using a database of cellular signatures8, we identify drugs that could modulate this pathway and validate the potent anti-inflammatory activity of one class of small molecules in vitro and ex vivo. Together, this highlights the potential for common genetic associations to improve both the understanding and treatment of human disease.

immunology↗

Bayesian clustering with uncertain data

Clustering is widely used in bioinformatics and many other fields, with applications from exploratory analysis to prediction. Many types of data have associated uncertainty or measurement error, but this is rarely used to inform the clustering. We present Dirichlet Process Mixtures with Uncertainty (DPMUnc), an extension of a Bayesian nonparametric clustering algorithm which makes use of the uncertainty associated with data points. We show that DPMUnc out-performs existing methods on simulated data. We cluster immune-mediated diseases (IMD) using GWAS summary statistics, which have uncertainty linked with the sample size of the study. DPMUnc separates autoimmune from autoinflammatory diseases and isolates other subgroups such as adult-onset arthritis. We additionally consider how DPMUnc can be used to cluster gene expression datasets that have been summarised using gene signatures. We first introduce a novel procedure for generating a summary of a gene signature on a dataset different to the one where it was discovered. Since the genes in the gene signature are unlikely to be as strongly correlated as in the original dataset, it is important to quantify the variance of the gene signature for each individual. We summarise three public gene expression datasets containing patients with a range of IMD, using three relevant gene signatures. We find association between disease and the clusters returned by DPMUnc, with clustering structure replicated across the datasets. The significance of this work is two-fold. Firstly, we demonstrate that when data has associated uncertainty, this uncertainty should be used to inform clustering and we present a method which does this, DPMUnc. Secondly, we present a procedure for using gene signatures in datasets other than where they were originally defined. We show the value of this procedure by summarising gene expression data from patients with immune-mediated diseases using relevant gene signatures, and clustering these patients using DPMUnc. Author SummaryIdentifying groups of items that are similar to each other, a process called clustering, has a range of applications. For example, if patients split into two distinct groups this suggests that a disease may have subtypes which should be treated differently. Real data often has measurement error associated with it, but this error is frequently discarded by clustering methods. We propose a clustering method which makes use of the measurement error and use it to cluster diseases linked to the immune system. Gene expression datasets measure the activity level of all ~20,000 genes in the human genome. We propose a procedure for summarising gene expression data using gene signatures, lists of genes produced by highly focused studies. For example, a study might list the genes which increase activity after exposure to a particular virus. The genes in the gene signature may not be as tightly correlated in a new dataset, and so our procedure measures the strength of the gene signature in the new dataset, effectively defining measurement error for the summary. We summarise gene expression datasets related to the immune system using relevant gene signatures and find that our method groups patients with the same disease.

bioinformatics↗

BBmix: a Bayesian Beta-Binomial mixture model for accurate genotyping from RNA-sequencing

MotivationWhile many pipelines have been developed for calling genotypes using RNA-sequencing data, they all have adapted DNA genotype callers that do not model biases specific to RNA-sequencing such as reference panel bias or allele specific expression. ResultsHere, we present BBmix, a Bayesian Beta-Binomial mixture model that first learns the expected distribution of read counts for each genotype, and then deploys those learned parameters to call genotypes probabilistically. We benchmarked our model on a wide variety of datasets and showed that our method generally performed better than competitors, mainly due to an increase of up to 1.4% in the accuracy of heterozygous calls. Moreover, BBmix can be easily incorporated into standard pipelines for calling genotypes. We further show that parameters are generally transferable within datasets, such that a single learning run of less than one hour is sufficient to call genotypes in a large number of samples. AvailabilityWe implemented BBmix as an R package that is available for free under a GPL-2 licence at https://gitlab.com/evigorito/bbmix and accompanying pipeline at https://gitlab.com/evigorito/bbmix_pipeline.

genomics↗

Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques

Type-I interferons (IFN-I) are critical mediators of innate control of viral infections, but also drive recruitment of inflammatory cells to sites of infection, a key feature of severe COVID-19. Here, and for the first time, IFN-I signaling was modulated in rhesus macaques (RMs) prior to and during acute SARS-CoV-2 infection using a mutated IFN2 (IFN-modulator; IFNmod), which has previously been shown to reduce the binding and signaling of endogenous IFN-I. In SARS-CoV-2-infected RMs, IFNmod reduced both antiviral and inflammatory ISGs. Notably, IFNmod treatment resulted in a potent reduction in (i) SARS-CoV-2 viral load in Bronchoalveolar lavage (BAL), upper airways, lung, and hilar lymph nodes; (ii) inflammatory cytokines, chemokines, and CD163+MRC1-inflammatory macrophages in BAL; and (iii) expression of Siglec-1, which enhances SARS-CoV-2 infection and predicts disease severity, on circulating monocytes. In the lung, IFNmod also reduced pathogenesis and attenuated pathways of inflammasome activation and stress response during acute SARS-CoV-2 infection. This study, using an intervention targeting both IFN- and IFN-{beta} pathways, shows that excessive inflammation driven by type 1 IFN critically contributes to SARS-CoV-2 pathogenesis in RMs, and demonstrates the potential of IFNmod to limit viral replication, SARS-CoV-2 induced inflammation, and COVID-19 severity.

immunology↗

High-resolution promoter interaction analysis in Type 3 Innate Lymphoid Cells implicates Batten Disease gene CLN3 in Crohn's Disease aetiology

Innate lymphoid cells (ILCs) are rare, tissue-resident innate lymphocytes that functionally mirror CD4+ T helper cell lineages but lack antigen receptors. Type 3 ILCs (ILC3s) are enriched in the gut, airways, and mucosal lymphoid tissues, where they regulate inflammation and promote barrier integrity. To define the regulatory architecture of primary human ILC3s, we map promoter-anchored chromosomal contacts using high-resolution, low-input Promoter Capture Hi-C (PCHi-C) in these cells alongside CD4+ T cells. By combining statistical detection with a PCHi-C-adapted Activity-by-Contact approach, we link promoters to distal regulatory elements, identifying hundreds of ILC3-specific contacts. We use these maps to connect genome-wide association study (GWAS) risk variants for Crohns disease to target genes using multiCOGS, a Bayesian framework that integrates PCHi-C with summary-statistic imputation and multivariate fine-mapping. This analysis highlights both known and unanticipated candidates, including CLN3, a causal gene for the neurodevelopmental Batten disease. Using a mouse ILC3-like cell line, we show that Cln3 is downregulated upon cytokine stimulation, and Cln3 overexpression alters stimulation-induced transcriptional programmes and cytokine secretion. Extending this approach, we generate a catalogue of ILC3-linked risk genes for five additional autoimmune conditions and show that they are enriched for regulators of the ILC3 inflammatory response identified in a CRISPR interference screen. Together, these findings illuminate long-range gene control in ILC3s and prioritise known and newly implicated autoimmune risk genes with potential roles in this clinically important cell type.

genetics↗

Accurate detection of shared genetic architecture from GWAS summary statistics in the small-sample context

Assessment of the genetic similarity between two phenotypes can provide insight into a common genetic aetiology and inform the use of pleiotropy-informed, cross-phenotype analytical methods to identify novel genetic associations. The genetic correlation is a well-known means of quantifying and testing for genetic similarity between traits, but its estimates are subject to comparatively large sampling error. This makes it unsuitable for use in a small-sample context. We discuss the use of a nonparametric test of genetic similarity first introduced by Li et al. for application to GWAS summary statistics. We establish that the null distribution of the test statistic is modelled better by an extreme value distribution than a transformation of the standard exponential distribution as originally recommended by Li and colleagues. We show with simulation studies and real data from GWAS of 18 phenotypes from the UK Biobank that the test is to be preferred for use with small sample sizes, particularly when genetic effects are few and large, outperforming the genetic correlation and another nonparametric statistical test of independence. We find the test suitable for the detection of genetic similarity in the rare disease context. Author summaryThe genome-wide association study (GWAS) is a method used to identify genetic variants which contribute to the risk of developing disease. These genetic variants are frequently shared between conditions, such that the study of the genetic basis of one disease can be informed by knowledge of another, similar disease. This approach can be productive where the disease in question is rare such that a GWAS has less power to associate variants with the disease, but there exist larger GWAS of similar diseases. Existing methods do not measure genetic similarity precisely when patients are few. Here we assess a previously published method of testing for genetic similarity between pairs of diseases using GWAS data, the GPS test, against three other methods with the use of real and simulated data. We present a new computational procedure for carrying out the test and show that the GPS test is superior to its comparators in identifying genetic similarity when the sample size is small and when the genetic similarity signal is less strong. Use of the test will enable accurate detection of genetic similarity and the study of rarer conditions using data from better-characterised diseases.

genetics↗